State Bills related to Drug Prices (2015 - 2018)
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

 
View only
 
 
ABCDEFGHIJKLMNOPQRSTUVWXYZAAABACADAE
1
StateBillYearTitleStatus (all)Status (simplified)Date of Last ActionAuthorNumber of authorsParty affiliation (all)
Party affiliation (simplified)
TopicsAssociated BillsGeneral summaryKey policyKey policy summaryInclusion criteriaScope of transparencySanctions
38
MassachusettsMA S 6272018Prescription Drug Price TransparencyPending - Senate Second ReadingPending2/22/2017Forry (D)1DemocraticDemocraticPricing and Payment - IndustryNone
Relates to cost control of pharmaceutical drug prices. Authorizes the state to appoint a commission to develop a list of the top 20 selling drugs in the state and other drugs based on an enumerated list of price and use factors. For each specified drug, manufacturers must provide a detailed set of reports including manufacturing and marketing costs, costs to public and private purchasers, and other specified factors. The Commission will promulgate regulations, violations may subject a manufacturer to penalties up to $100,000 for each failure to comply. [updated 8/15/17]
R&D transparency
Manufacturers of drugs with price increases shall report total R&D cost, clinical trials costs, subsidies
Drugs with price increases
R&D costs, clinical trial costs, subsidies
39
MassachusettsMA S 6522018Pharmaceutical Price Gouging PreventionPending - Senate Second ReadingPending2/22/2017Montigny (D)1DemocraticDemocratic
Pricing and Payment - Industry, Cost Sharing and Deductibles - Consumers
None
Promotes transparency and prevent price gouging of pharmaceutical drug prices.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment, with price increases, and 10 costliest drugs shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices and price increasesR&D costs, clinical trial costs
40
MassachusettsMA S 6522017Pharmaceutical Price Gouging Prevention
Pending - Joint Committee on Health CareFinancing
Pending2/22/2017Montigny (D)1DemocraticDemocratic
Pricing and Payment - Industry, Cost Sharing and Deductibles - Consumers
None
Promotes transparency and prevent price gouging of pharmaceutical drug prices.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment, with price increases, and 10 costliest drugs shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices and price increasesR&D costs, clinical trial costs
45
NevadaNV A 2152017
Reporting of Information Relating to Prescription Drugs
Failed - DiedFailed2/13/2017Joiner (D)1DemocraticDemocraticPricing and Payment - IndustryNone
Requires Rx manufacturers to reporting of certain information on drugs with a wholesale price of at least $10,000 or an annual price increase of 25%, relating to the manufacturer's cost associated with their prescription drugs.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment or with price increases shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices and price increases
R&D costs, clinical trial costs, subsidies
50
New YorkNY A 29392018Prescription Drug Cost Transparency
Pending - Assembly Health Committee
Pending1/23/2017
McDonald J (D) Additional Authors: Ortiz (D);Morinello (R);Walsh (R)
4BipartisanBipartisanPricing and Payment - IndustryNone
Relates to prescription drug cost transparency.
R&D transparency
Manufacturers of drugs with wholesale prices of 1,000 or more per month or with price increases shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices and price increases
R&D costs, clinical trial costs, subsidies
51
New YorkNY A 29392017Prescription Drug Cost Transparency
Pending - Assembly Health Committee
Pending1/23/2017
McDonald J (D) Additional Authors: Ortiz (D);McDonald J (D);Morinello (R);Walsh (R)
5BipartisanBipartisanPricing and Payment - IndustryNone
Relates to prescription drug cost transparency.
R&D transparency
Manufacturers of drugs with wholesale prices of 1,000 or more per month or with price increases shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices and price increases
R&D costs, clinical trial costs, subsidies
72
VirginiaVA H 14362018Prescription Drug Price TransparencyFailed - DiedFailed1/16/2018
Hurst (D) Additional Authors: Plum (D);Edwards (D);Hope (D);Simon (D);Boysko (D);Krizek (D);Levine (D);Gooditis (D)
9DemocraticDemocratic
Pricing and Payment - Industry, Insurance/Coverage - Rx Drugs
None
Relates to prescription drug price transparency, requires every manufacturer of a prescription drug that is made available in the state and has a wholesale acquisition price of $10,000 or more for a single course of treatment to report to the State Health Commissioner no later than July 1 of each year information related to the cost of developing, manufacturing, and marketing the prescription drug.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per treatment or with price increases shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices and price increases
R&D costs, clinical trial costs, subsidies
76
WashingtonWA S 55862018Prescription Drug Cost Transparency
Failed - Adjourned - IndefinitelyPostponed
Failed1/30/2017Ranker (D)1DemocraticDemocratic
Pricing and Payment - Industry, Cost Sharing and Deductibles - Consumers
None
Addresses prescription drug cost transparency, requires the state to collect, verify, and summarize prescription drug pricing data provided by health insurance issuers and manufacturers. A manufacturer with a drug that increases more than 10% or $10,000 in a year must report for such drug, the time on the market, the generic or brand name status, pricing history in the US the previous five years, total financial assistance given by the manufacturer through assistance programs, rebates, and coupons, and an economic justification of the qualifying price increase for the covered drug. Any qualifying price increase for a covered drug must be announced 60 days before the change. Separately, each health insurance plan issuer must identify overall spending on prescription drugs and by the 25 most frequently prescribed drugs, the 25 costliest prescription drugs, with the information by the state Medicaid program, public employees' benefits board programs, and the individual, small group, and large group markets. All data submitted must be collected by a state-approved data organization and made publicly available on the office's web site, with reports due starting Nov. 1, 2017. Fines may be up to $1000 per day for non-compliance.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment or with price increases shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices and price increases
R&D costs, clinical trial costs, subsidies
77
WashingtonWA S 54012018Prescription Drug Cost Transparency
Failed - Adjourned - Senate Health & LongTerm Care Committee
Failed1/23/2017Rivers (R)1RepublicanRepublican
Pricing and Payment - Industry, Insurance/Coverage - Rx Drugs
WA H 1541 - Companion
Addresses prescription drug cost transparency, requires the state to collect, verify, and summarize prescription drug pricing data provided by health insurance issuers and manufacturers. A manufacturer with a drug that increases more than 10% or $10,000 in a year must report for such drug, the time on the market, the generic or brand name status, pricing history in the US the previous five years, total financial assistance given by the manufacturer through assistance programs, rebates, and coupons, and an economic justification of the qualifying price increase for the covered drug. Any qualifying price increase for a covered drug must be announced 60 days before the change. Separately, each health insurance plan issuer must identify overall spending on prescription drugs and by the 25 most frequently prescribed drugs, the 25 costliest prescription drugs, with the information by the state Medicaid program, public employees' benefits board programs, and the individual, small group, and large group markets. All data submitted must be collected by a state-approved data organization and made publicly available on the office's web site, with reports due starting Nov. 1, 2017. Fines may be up to $1000 per day for non-compliance.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment or with price increases shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices and price increases
R&D costs, clinical trial costs, subsidies
78
WashingtonWA S 55862017Prescription Drug Cost Transparency
Pending - Carryover - Senate Health Care Committee
Pending1/30/2017Ranker (D)1DemocraticDemocratic
Pricing and Payment - Industry, Cost Sharing and Deductibles - Consumers
None
Addresses prescription drug cost transparency, requires the state to collect, verify, and summarize prescription drug pricing data provided by health insurance issuers and manufacturers. A manufacturer with a drug that increases more than 10% or $10,000 in a year must report for such drug, the time on the market, the generic or brand name status, pricing history in the US the previous five years, total financial assistance given by the manufacturer through assistance programs, rebates, and coupons, and an economic justification of the qualifying price increase for the covered drug. Any qualifying price increase for a covered drug must be announced 60 days before the change. Separately, each health insurance plan issuer must identify overall spending on prescription drugs and by the 25 most frequently prescribed drugs, the 25 costliest prescription drugs, with the information by the state Medicaid program, public employees' benefits board programs, and the individual, small group, and large group markets. All data submitted must be collected by a state-approved data organization and made publicly available on the office's web site, with reports due starting Nov. 1, 2017. Fines may be up to $1000 per day for non-compliance.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment or with price increases shall report R&D costs, clinical trials costs
Drugs with high prices and price increasesR&D costs, clinical trial costs
Loading...
Main menu